ARTICLE | Clinical News

Raplixa: Additional Phase III data

November 10, 2014 8:00 AM UTC

Additional data from the single-blind, international Phase III FINISH-3 trial in 719 patients undergoing spinal, liver, vascular or soft tissue surgery showed that Raplixa significantly reduced time to hemostasis, the primary endpoint, in all 4 surgical indications vs. a gelatin sponge alone (p<0.001 for all). Raplixa also significantly improved restricted mean time to hemostasis (p<0.0001) and probability of hemostasis at 3 minutes (p<0.0001) and 5 minutes (p<=0.002) vs. a gelatin sponge alone. Data were presented at the American College of Surgeons meeting and published in the Journal of the American College of Surgeons. Previously reported data showed that Raplixa met all primary and secondary hemostasis efficacy endpoints vs. a gelatin sponge alone (see BioCentury, Aug. 12, 2013). ...